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Abstract
Background: Controversy exists in predicting costly hospitalization in patients with chronic kidney disease and
co-morbid conditions. We therefore tested associations between serum chemistry values and the occurrence of
in-patient hospital costs over a thirteen month study period. Secondarily, we derived a linear combination of
variables to estimate probability of such occurrences in any patient.
Method: We calculated parsimonious values for select variables associated with in-patient hospitalization and
compared sensitivity and specificity of these models to ordinal staging of renal disease.
Data from 1104 de-identified patients which included 18 blood chemistry observations along with complete claims
data for all medical expenses.
We employed multivariable logistic regression for serum chemistry values significantly associated with in-patient
hospital costs exceeding $3,000 in any single month and contrasted those results to other models by ROC area
curves.
Results: The linear combination of weighted Z scores for parathyroid hormone, phosphorus, and albumin
correlated with in-patient hospital care at p < 0.005. ROC curves derived from weighted variables of age, eGFR,
hemoglobin, albumin, creatinine, and alanine aminotransferase demonstrated significance over models based on
non-weighted Z scores for those same variables or CKD stage alone. In contrast, the linear combination of
weighted PTH, PO4 and albumin demonstrated better prediction, but not significance over non-weighted Z scores
for PTH alone.
Conclusion: Further study is justified to explore indices that predict costly hospitalization. Such metrics could assist
Accountable Care Organizations in evaluating risk adjusted compensation for providers.
Background
Patients with chronic kidney disease (CKD) are at risk for
complications requiring costly hospital care. However
predicting which patients are at risk for high cost hospi-
talization has been a difficult endeavor. Cardiovascular
d i s e a s e( C V D )i sac o - m o r b i d i t yt h a td r i v e sm a n yc o s t s
[1-3]. In addition, CKD patients often display dysfunction
of the endocrine system that distorts the balance between
calcium, phosphate and parathyroid hormone leading to
calcification of the arterial tree and aggravation of hyper-
tension and CVD along with costly hospitalization [4-6].
Some investigators have suggested that serum PTH
levels can predict cardiovascular events [7-9]. Numerous
animal studies have confirmed these observations for ele-
vated PTH levels [10-13]. Further, it is suggested that
high levels of PTH contribute to hyperlipedemia and
impaired glucose tolerance [14-17].
Disorders in mineral metabolism have become a focal
point for predicting costly hospitalization. Covic et al in a
comprehensive review of the literature reported a signifi-
cant rise in all-cause mortality associated with serum
mineral disturbances [18]. Their review suggested that
abnormal plasma levels of phosphorus, followed by calcium
and parathyroid hormone increased mortality. However, as
cautioned by the authors, the most articles reported on
patients with end stage renal disease (ESRD). In a subse-
quent study, Bhuriya et al analyzed PTH levels in patients
with CVD and stage 3 and 4 CKD [19]. Employing multi-
variable logistic regression analysis, they reported on the
association of age, hemoglobin level, eGFR, plasma PTH,
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analysis demonstrated that PTH levels greater than 70 pg/
ml increased the risk for CVD significantly. However, they
found no relationship with levels of serum phosphorus or
calcium.
On the other hand, other investigators have demon-
s t r a t e dt h a te l e v a t e da l k a l i n ep h o s p h a t a s ep r e d i c t e d
mortality and hospitalization in hemodialysis patients
independent of calcium, phosphorus, and PTH levels
[20].
Serum albumin associated with calcium binding is
another factor linked with increased morbidity in CKD
patients. Since low serum albumin is frequently seen
with protein energy malnutrition, it has been suggested
as a predictor for increased mortality in CKD patients
[21-23].
In summary, chronic kidney disease is clearly associated
with multiple organ dysfunctions that impact cost, dimin-
ish health and work productivity [24-29]. However as seen
in the literature, there is disagreement as to which blood
chemistry values reliably predict illness complexity and
high cost healthcare. Since CKD afflicts up to 20 million
Americans and accounts for annual dialysis costs of
$121,000 per patient with ESRD, the ability to predict
high-cost care in chronic disease is vital for future
Accountable Care Organizations. In this study, we investi-
gated if measurement of blood chemistry values would
add additional information over ordinal staging of renal
disease and therefore improve the management of CKD
patients.
We analyzed the association of each blood chemistry
variable on the probability of hospitalization, and did so
under the assumption that the influence of each variable is
through its impact on a linear predictor. The result pro-
vides an association of each variable to the probability for
an adverse outcome.
Objective
The objective of this study was to investigate the relation-
ship between select serum chemistry values and the occur-
rence of in-patient hospital payments exceeding $3,000 in
a n ys i n g l em o n t hf o rar a n g e of CKD patients. Next, we
compared those results to other predictive models based
on non-weighted Z scores of the same serum values or to
ordinal stages of CKD in the same patients.
Method
Samples Analyzed
Our data set included 1104 de-identified patients from the
kidney disease registry of a local managed care organiza-
tion (MCO), who had received treatment from November
2007 through November 2008. This data was obtained
after review of the study protocol by the university’s school
of medicine Institutional Review Board (IRB) and permis-
sion from the regional MCO.
Since our goal was to study the relationship between a
select series of blood chemistry values and high hospital
cost in CKD patients, we employed the definition of CKD
as two or more recordings of eGFR at or below 60 ml/min
over a three month period. In the dataset supplied to us,
CKD was confirmed in 888 patients. The remaining 216
excluded patients had no eGFR values recorded at any
time over the 13 month study period. In addition within
this excluded group, 212 patients had one or more serum
glucose recordings, and 139 had one or more abnormal
serum creatinine values with no other blood tests recorded
at any time. These excluded patients appeared on the renal
registry because their primary-care physician assigned a
diagnostic code (ICD-9) indicating acute or chronic renal
disease or a family history of CKD with diabetes.
Variable Definitions
A total of eighteen blood tests were requested from the
MCO for analysis in this study by a consulting group of
university nephrologists. The test choices were made
based on each variable’s perceived importance in monitor-
ing the health of CKD patients. The 18 blood tests were:
serum urate, phosphorus (PO4), parathyroid hormone
(PTH), glucose, glycolated hemoglobin (HbA1c), hemoglo-
bin (HGB), bicarbonate, albumin, creatinine, urea nitrogen
(BUN), potassium, calcium, sodium, alkaline phosphatase,
alanine aminotransferase (ALT), bilirubin, leukocytes, and
eGFR (by MDRD4). The data set also included the com-
plete financial profile for all medical claims that were paid
for these patients over the same time period. These costs
were linked to lab records using SQL queries written to
join lab and claims data by unique patient identifiers
within each dataset and allowed reimbursements to be
studied.
Since tests ordered by physicians showed marked varia-
tion in selection and repetition, we sorted the remaining
pool of 888 patients into two data sets for two separate
sets of modeling analyses based on the following criterion:
(1), 267 patients with no missing observations for serum
parathyroid hormone (PTH) in order to focus on mineral
metabolism disorders; and (2) 792 patients with no miss-
ing observations for serum creatinine in order to focus on
serum values associated with renal function. Several mod-
els with various sets of explanatory variables were fitted
using each of these data sets. Each model was fitted to the
data for the subset of all patients in the respective data
sets with non-missing values for every variable in the
model.
The blood tests for all patients were performed by the
same laboratory. Thus, the units of measurement and nor-
mal range for each test were common to all observations.
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were calculated for each lab test by averaging the tests
results over all times of observation. Except for HbA1c
and eGFR, the mid-point of the normal range for each test
was taken as the mean, and the range divided by four as
the standard deviation for a non-diseased normal popula-
tion. Each lab test was standardized using this mean and
standard deviation to obtain a Z-score for each variable
for each patient.
Costs were totaled within each month and used, along
with the codes for service provider type (e.g. hospital,
surgery, internal medicine, nephrology, family medicine,
pharmacy, etc) to define cost allocation. The frequency
distribution for all hospital reimbursements displayed a
bimodal curve with $3000 as the best dividing point
between the two modes. We therefore selected this value
as a cutoff point. This decision was further justified by
the fact that total payments which exceeded $3000 were
primarily for in-patient hospital care. That variable was
defined as outcome 1. We chose to name this outcome
as “High-Cost Hospitalization” or HCH to allow for the
possibility that hospital care could be associated with
reimbursements less than $3000. Other patients not
meeting this criterion were assigned an outcome value of
0, or non-HCH.
Study Outline
The primary purpose of our study was to test the associa-
tions between a CKD patient’s serum chemistry values
and the occurrence of HCH in any single month over the
thirteen-month study period. Secondarily, we derived a
linear combination of blood tests to estimate the probabil-
ity of HCH for any given patient. Next, we tested the asso-
ciation of a patient’s CKD stage to the occurrence of HCH
under the same criterion. Next the sensitivity and specifi-
city for predicting HCH was calculated for a sequence of
cut-points on each linear predictor scale by comparing
predicted values of HCH to the occurrence of true positive
and true negative HCH. Finally, the predictive models
were compared through calculation of areas under receiver
operating characteristic (ROC) curves.
Statistical Methods
As discussed previously, some investigators conclude that
measurement of PTH, phosphorus, calcium, alkaline phos-
phatase, albumin and eGFR predict illness severity and
hospitalization in renal patients. To test for this associa-
tion, we modeled the probability of HCH as a multivari-
able logistic function of average age, eGFR, and the
Z-scores calculated from the average measures of PTH,
phosphorus, bicarbonate, albumin, potassium, calcium,
sodium, alkaline phosphatase and eGFR, over the 13
month period. A backward selection model building
strategy was employed to derive a parsimonious model
containing only significant predictors. At each step, the
explanatory variable with the highest p-value greater than
0.10 was deleted. If its deletion resulted in another variable
that had been significant (p < 0.10) previously becoming
non-significant, then the deleted variable was added back
into the model and the variable with the next largest p-
value greater than 0.10 was deleted. These steps were
repeated until only significant variables (p < 0.10)
remained in the model.
These analyses produced a regression table with an esti-
mated constant and regression coefficients for each expla-
natory variable in the final model, along with calculated p-
values. The Hosmer-Lemeshow Goodness-of-Fit test was
calculated to test for a lack of fit of the final model. Prob-
ability curves were created relating the linear predictor
(i.e., the weighted sum of predictor variables with weights
that are the estimated coefficients from the logistic regres-
sion) to the probability of HCH.
The initial data set focused on analyses of mineral meta-
bolism and contained 267 patients; the second analysis
focused on 792 patients and used other available blood
chemistry values. Employing the data set with 792 patients,
the multivariable logistic regression model building strat-
egy described above was employed to derive a parsimo-
nious model containing the significant predictors for HCH
from among the following variables: age and Z-scores for
blood glucose, hemoglobin, bicarbonate, albumin, creati-
nine, urea nitrogen, potassium, calcium, sodium, alkaline
phosphatase, ALT, and white blood cell count (leuko-
cytes). As above, the goodness of fit of the final model was
tested using the Hosmer-Lemeshow test.
For the logistic regressions described above, the number
of observations used to fit each model was the number
with non-missing values of all variables in the model. All
computations were done using the Minitab package of
statistical software.
We calculated the sensitivity and specificity for each
model based on a series of cut-points on the linear predic-
tor scale for the final multivariable logistic regression
models. We then compared resulting predicted values to
t h eo c c u r r e n c eo ft r u ep o s i t i v ea n dt r u ef a l s ev a l u e sf o r
HCH and calculated sensitivity and specificity for each
cut-point. The same calculations were made for cut-points
on the linear predictor obtained from the CKD stage
model for predicting HCH. Similarly, calculations were
made for a series of cut-points on the linear predictors
defined by the sum of non-weighted Z scores in both the
mineral metabolism and renal models for the occurrence
of HCH. Lastly, ROC curves were calculated for each
model along with an area under each respective curve in
order to compare models for accuracy in predicting HCH.
ROC curves and areas under the curves were calculated
using the software application by Eng J. ROC analysis:
web-based calculator for ROC curves. Baltimore: Johns
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Results
For the total pool of CKD patients in this study, analysis
of the claims data revealed that 435 patients had at least
one HCH (i.e., HCH = 1) month. The remaining 453
patients had no HCH during the 13 study-months
(HCH = 0).
The average annual payment per patient for the group
designated non-HCH (outcome 0) was $3,167 with a
range of $264 to $17,197. The average monthly payment
per patient in this group was $313.
In contrast, the HCH (outcome 1) group had average
annual payments of $35,892 with a range of $4,276 to
$314,533. Their average monthly per patient payment
was $3,136.
Figure 1 is a stacked histogram demonstrating the
average yearly payments per patient. Payments for hos-
pital only services are shown in light gray, and payments
for other medical services shown in black for both the
HCH and non-HCH groups. In the HCH group, pay-
ments for hospital only services averaged $31,242 per
patient with a range of $3,068 to $307,906. Other medi-
cal services for those same patients had average annual
payments per patient of $4,671 with a range of $55 to
$25,153.
On the other hand in the non-HCH (outcome 0)
group, payments for hospital only services averaged
$830 per patient with a range of $0 to $5,865. For other
medical services, that average total payment per patient
was $2,652 with a range of $264 to $16,572.
For the 267 patients with repeated PTH and serum
phosphate testing, logistic regression analysis demon-
strated a significant association between increasing PTH
levels and HCH at p < 0.005. The Hosmer-Lemeshow
Goodness-of-Fit test p-value was calculated at 0.06 with
66.5% concordant pairs between the response variable
and the predicted probabilities.
For those variables associated in the literature with
mineral metabolism disorders (age, PTH, phosphorus,
bicarbonate, albumin, potassium, calcium, sodium, alka-
line phosphatase, eGFR) their overall p-value for correla-
tion with HCH was significant at p < 0.005, nonetheless,
a number of variables had p-values that were not signifi-
cant. After a step-wise elimination of the least signifi-
cant variable, the regression calculation for the most
parsimonious model demonstrated that PTH, phos-
phorus and albumin had significance at p < 0.005 with a
Chi-Square Goodness of Fit test that was not significant
(p = 0.83). In addition, there was an association of
74.3% concordant pairs between the response variables
and predicted probabilities.
Using the calculated regression coefficients for the lin-
ear predictor’s constant and PTH, phosphate, and albu-
min coefficients, we calculated a probability curve for
HCH as a function of the linear predictor, using the fol-
lowing formula for probability of HCH given e
lp/(1+e
lp),
where
lp = −1.21+0.03∗PTH z−score + 0.36∗PO4 z−score − 0.54 ∗ albumin z−score.
By calculating e
lp/(1+e
lp) for each patient and plotting
versus the linear predictor (lp) we produced the curve
shown in Figure 2.
The probability for HCH increased sharply to 50% as
the linear predictor for serum PTH, phosphorous and
albumin increased from 0.0 to 1.0. With an increase of
the linear predictor to 2.0, the probability for HCH rose
to 65%. As the linear predictor increased to 4.0, the
probability for HCH reached 80%. And as the linear
Figure 1 Comparison of High Cost Hospital (HCH) group to
non-High Cost Hospital (non-HCH) group. Stacked histogram
comparing average annual total per patient healthcare payments in
the HCH and non-HCH groups. Black equals payments for
physicians and other medical services; gray equals payments for
hospital services only.
Figure 2 Probability curve for patients with hospital care costs
exceeding $3,000 monthly. Probability of Hospital Care exceeding
$3,000 in any single month versus the linear predictor (lp) of the
logit calculation for average serum levels of PTH, phosphate and
albumin.
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HCH increased to 90%.
In order to tabulate the impact of individual variables
on the outcome of HCH, we calculated individual prob-
ability curves for PTH, phosphorus and albumin. By
holding each of the non-selected variables at Z-score =
0, we recalculated logistic regression values and subse-
quent probability values. For Z-scores of PTH at 20, 40
and 70, the probability of HCH was 34%, 50% and 72%
respectfully. For Z-scores of phosphorus at 2, 4, 6, the
probability of HCH was 36%, 55%, and 70% respectively.
For Z-scores of albumin at -2.0, -3.0 and -4.0, the prob-
ability of HCH was 42%, 55%, and 69% respectively.
Since the reference range for normal can vary in dif-
ferent laboratories, practicing clinicians can calculate the
Z-scores for their patient’s test values and substitute
those values within the above formulas in order to cal-
culate patient specific probabilities.
Since the data pool for renal patients with serum test-
ing other than PTH and phosphorous was considerable
larger (792), we calculated logistic regression coefficients
for the variables of age, glucose, hemoglobin, bicarbo-
nate, albumin, creatinine, BUN, potassium, calcium,
sodium, alkaline phosphatase, ALT, leukocytes, eGFR
and to achieve the most parsimonious model each vari-
able with the least significant value was eliminated in a
step wise fashion and the logistic regression recalculated.
The final list consisted of age, hemoglobin, albumin,
creatinine, ALT, and eGFR.
This calculation had p < 0.005 and a Chi-Square
Goodness of Fit test by the Hosmer-Lemeshow method
that was not significant at the 0.40 level. In addition, the
association between the response variable and the pre-
dicted probabilities had 69.9% concordant pairs.
Calculation of a probability curve for the outcome of
HCH over the study period versus the linear predictor
for those variables is displayed in Figure 3.
Figure 3 illustrates the steep rise in probability for
HCH to 67% as the linear predictor increased from 0.0
to 2.5. As the curve begins to plateau at a predictor
value of 3.0 to 5.0, the probability of HCH increased
from 67% to 82%. With an increase in predictor values
from 10.0 to 17.0, the probability for HCH rose from
90% to 97%.
Figure 4 is the ROC area curve based on a sequence
of cut-points on the linear predictor defined by the
weighted Z scores of PTH, PO4, and albumin.
T h eA r e au n d e rt h eC u r v e( A U C )s h o w ni nF i g u r e4
was calculated at 0.68. This value was compared to the
AUC for a model based on the sum of the non-weighted
Z scores for PTH, PO4 and albumin. The AUC for that
curve was 0.64. Significance of the difference between
these two curves revealed, as expected, a p-value > .05.
In a similar manner, the AUC derived from the Z score
of PTH alone, as well as for stages of CKD, both had
areas of 0.64.
For the cohort of 792 patients, the AUC derived from
the linear combination of predictor values for age,
serum hemoglobin, albumin, creatinine, ALT and eGFR
compared to the true positive occurrence for HCH had
an area of 0.699.
In contrast, Figure 5 demonstrates the ROC curve com-
paring CKD stage to the true positive occurrence of HCH.
That AUC was calculated at 0.585. The significance of the
difference between the AUC shown in Figures #4 and #5
demonstrated significance at p < 0.005.
In a similar manner, The ROC area curves based on
the sum of the non-weighted Z scores for hemoglobin,
creatinine, albumin and ALT was calculated at 0.472,
a n dw h e nc o m p a r e dt oA U Cf o rF i g u r e# 4d e m o n -
strated significance at p < 0.0005. Similarly, the AUC
Figure 3 Probability curve for high cost hospitalization versus
the linear regression calculation for age and select blood
chemistry values. Probability for Hospitalization versus the linear
progression for age, serum levels for hemoglobin, albumin,
creatinine, alanine aminotransaminase, and e-GFR.
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Figure 4 Receiver operating curve (ROC) curve for PTH, PO4
and serum albumin versus HCH. The center diamond line
represents the true positive fraction(TPF) for HCH in patients with a
calculated sum for the linear predictor defined as the linear
combination for PTH, PO4 and albumin. The upper and lower gray
lines represent the 95% confidence levels. The Y axis = True Positive
Fraction (i.e. Sensitivity) versus the X axis for False Positive Fraction
(i.e. 1-specificity).
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true positive and true negative occurrence of HCH was
calculated at 0.414 and when compared to Figure #4
demonstrated a significance at p < 0.0005.
Discussion
Our study suggests a linear combination of select serum
values correlates with prediction of in-patient hospital
care (HCH) for CKD patients defined as payments in
excess of $3,000 in one or more months over a one year
study period.
Although there is controversy in the literature over
which mineral metabolites are most significantly related
to morbidity and mortality, our investigation found that
the sum of a linear combination of beta weighted Z
scores for PTH, phosphorous and albumin correlated sig-
nificantly with the outcome of HCH.
Given the limited pool of 267 patients with regular test-
ing for serum parathyroid hormone and phosphorus, our
findings justify further exploration of this promising rela-
tionship. Initially we questioned whether patients with
tests for PTH and phosphorus had more advanced renal
disease than our second cohort of 792 patients without
such testing. However the average CKD stage for patients
in the first and second cohorts was: 3.8 and 3.6
respectively.
The area under the ROC curve for the linear combina-
tion of weighted values for PTH, PO4 and albumin was
greater, but not significantly different, than the areas
under ROC curves for the non-weighted sum of Z scores
for PTH, PO4 and albumin or for the Z score of PTH
alone. The association of true positive HCH with the Z
score for PTH alone was intriguing to us. The Z scores
for average PTH within our patient pool ranged from
-2.1 to 79.7, with a mean value of 5.9. This wide variation
was not observed in the average Z scores for PO4 or
albumin which ranged from -3.6 to 8.1 (mean 0.9), and
from -4.9 to 1.2 (mean -1.0) respectively. The wide varia-
tion for PTH and its strong correlation with HCH is con-
sistent with other researchers [19]. But this finding is
contrasted to other studies analyzing the association of
single blood tests to average cost for healthcare [30].
These latter investigators concluded that deviation of sin-
gle blood tests from their normal range did not predict
healthcare costs. We generally agree with that conclu-
sion, and further suggest that measurement of multiple
serum variables within a related system such as mineral
metabolism disorders or renal dysfunction may improve
prediction modeling and correlation to cost. We plan
future studies to expand our pool with no missing obser-
vations for variables associated with mineral metabolism
and renal function. With greater access to data from elec-
tronic health records, we postulate that addition of physi-
cal measures such as systolic blood pressure and BMI
may further improve predictive modeling.
Our second cohort of 792 patients with more complete
observations and weighted Z scores displayed better cor-
relation to the true positive occurrence of HCH. That
model differed significantly from the model based on
non-weighted Z scores of the same blood tests or for
stages of CKD.
As public policy supports sizable investments in electro-
nic health records, along with regional health information
exchanges, there is rapid movement towards Accountable
Care Organizations within the United States. Since ACOs
intend to shift provider focus from procedure pricing to
better health outcomes, the incentive for achieving this
goal is financial compensation based on individual patient
outcome. Such a shift will require metrics to predict
expected outcomes for patients in various stages of illness.
Currently most payers rely on claims data for prediction.
Such analysis is population based and does not recognize
individual patient complexity.
In order to tailor prevention for better health, improved
disease modeling is necessary. Accurate forecasts based on
objective data will also enhance delivery of value-based
outcomes.
We believe that further investigation is warranted to
evaluate additional linear combinations of diagnostic mea-
sures for select chronic illnesses in order to achieve these
goals.
Study Limitations
The primary limitations of our study deal with popula-
tion size, blood test selection by both primary care physi-
cians and specialists, as well as lack of data residing on
the medical record such as: micro-albuminuria, systolic
and diastolic blood pressure, along with BMI (Body Mass
Index). We are engaged in follow on studies, which
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Figure 5 Receiver operating curve (ROC) for HCH versus CKD
stage. The center diamond line represents the True Positive Fraction
(TPF) for HCH compared to the stage of CKD. The upper and lower
gray lines represent the 95% confidence levels. The Y axis = True
Positive Fraction (i.e. Sensitivity) versus the X axis for False Positive
Fraction (i.e. 1-specificity).
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data pool to additional MCO’s. With the advent of signif-
icant federal and state investments in electronic health
records and the establishment of regional health informa-
tion organizations (RHIO), we have undertaken the
necessary consent procedures to acquire more complete
physical and laboratory data on confirmed CKD patients.
Conclusion
In conclusion, our study demonstrates that:
1: A linear combination of blood tests based on Z
scores for PTH, PO4, and albumin derived from a mul-
tivariate logistic regression model correlates significantly
with in-patient hospital payments (HCH) exceeding
$3,000 in one or more months over a 13 month study
period at p < 0.005.
2: Summing the exponential values for the regression
coefficients derived from the logistic regression for
those variables divided by one plus the exponential lin-
ear progression for those same variables produced a
probability curve predicting HCH.
3: Calculation of a probability curve for the occur-
r e n c eo fH C Hi no n eo rm o r em o n t h sd u r i n gt h es t u d y
period based on the linear progression of the variables
for age, serum hemoglobin, albumin, creatinine, ALT
and eGFR demonstrated significance at p < 0.005.
4: Calculation of receiver operating characteristic
(ROC) curves for the models predicting HCH based on
the linear combination of age, hemoglobin, albumin,
creatinine, ALT, and eGFR demonstrated significance at
p < 0.005 when compared to ROC area calculations for
models based on the non- weighted Z scores for those
same variables or CKD stage alone.
5: In contrast, ROC area curves derived from a linear
combination of values derived from weighted variables
for PTH, PO4, and albumin demonstrated prediction
that was better, but not significantly different, than ROC
area curves calculated for the non-weighted Z scores for
those same variables as well as PTH alone.
6: Our findings suggest that multivariate logistic
regression calculations based on blood chemistry values
related to illness severity and reimbursement may have
value to future accountable care organizations in creat-
ing risk adjusted compensation models for providers. In
addition, these predictive models may have value in ear-
lier identification of patients for targeted prevention
therapy.
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